Clinical trial accrual among new cancer patients at a community‐based cancer center

• Published in: Cancer 2006-01, Vol.106 (2), p.426-433
• Main Authors: Go, Ronald S., Frisby, Kathleen A., Lee, Jennifer A., Mathiason, Michelle A., Meyer, Christine M., Ostern, Jodi L., Walther, Sara M., Schroeder, Jonean E., Meyer, Lori A., Umberger, Kathryn E.
• Format: Article
• Language: English
• Subjects: accrual; barriers; cancer; Cancer Care Facilities; clinical trial; Clinical Trials as Topic - standards; Humans; Neoplasms - diagnosis; Patient Education as Topic; Patient Participation; Patient Selection; patients; Physician-Patient Relations; Residence Characteristics
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.21597

BACKGROUND To the authors' knowledge, only limited data are available regarding clinical trial accrual patterns and the barriers encountered among newly diagnosed patients seen at community‐based cancer centers. METHODS In the current study, the authors prospectively collected clinical and sociodemographic data from all adult patients seen at a community‐based cancer center who had new cancers diagnosed between 2003–2004. Clinical trial enrollment decisions were noted and factors that prevented accrual were identified. RESULTS There was a total of 1012 new cancer patients. In 587 patients (58%), clinical trials appropriate for the diagnosis and stage of disease were not available. Among those patients for whom trials were available, 19.8% did not meet eligibility criteria, and only 9.9% of patients were enrolled. Although more trials were found to be available for women compared with men (51% vs. 32%; P < 0.01), the accrual rates were equal (11.2% vs. 7.6%; P = 0.24). Elderly patients comprised approximately 59.4% of those patients with available trials, but they were less likely to be enrolled (5.1% vs. 16.8%; P < 0.01). The major barriers to nonparticipation can be grouped into protocol limitations (68.1%), physician triage (16%), and patient decisions (15.9%). The overall accrual rate when all patients were included was 4% (42 of 1012 patients). CONCLUSIONS At the study institution, participation in clinical trials is reported to be low. The unavailability of appropriate clinical trials represents the most significant barrier. Continuing efforts to encourage physicians and to educate patients remain necessary. If the current study findings are found to be applicable to other community‐based cancer centers, making a larger variety of clinical trials available to the community may help to improve the accrual of patients to national cancer clinical trials. Cancer 2006. © 2005 American Cancer Society. At the study institution, the unavailability of appropriate clinical trials represents the most important barrier to clinical trial accrual among newly diagnosed cancer patients. If the findings of the current study are found to be applicable to other community‐based cancer centers, making a larger variety of clinical trials available to the community may help to improve the accrual of patients to national cancer clinical trials.